AIMS: Severity of outcome in COVID-19 is disproportionately higher among the obese, males, smokers, those suffering from hypertension, kidney disease, coronary heart disease (CHD) and/or type 2 diabetes (T2D). We examined if serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were altered in these high-risk groups. METHODS: Associations of serum ACE2 levels to hypertension, T2D, obesity, CHD, smokers and males in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavik Study (AGES-RS) of the elderly (mean age 75+/-6 years). RESULTS: Smokers, males, and individuals with T2D or obesity have altered serum levels of ACE2 that may influence productive infection of SARS-CoV-2 in these high-risk groups. CONCLUSION: ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.
AIMS: Severity of outcome in COVID-19 is disproportionately higher among the obese, males, smokers, those suffering from hypertension, kidney disease, coronary heart disease (CHD) and/or type 2 diabetes (T2D). We examined if serum levels of ACE2, the cellular entry point for the coronavirusSARS-CoV-2, were altered in these high-risk groups. METHODS: Associations of serum ACE2 levels to hypertension, T2D, obesity, CHD, smokers and males in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavik Study (AGES-RS) of the elderly (mean age 75+/-6 years). RESULTS: Smokers, males, and individuals with T2D or obesity have altered serum levels of ACE2 that may influence productive infection of SARS-CoV-2 in these high-risk groups. CONCLUSION:ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Iziah E Sama; Alice Ravera; Bernadet T Santema; Harry van Goor; Jozine M Ter Maaten; John G F Cleland; Michiel Rienstra; Alex W Friedrich; Nilesh J Samani; Leong L Ng; Kenneth Dickstein; Chim C Lang; Gerasimos Filippatos; Stefan D Anker; Piotr Ponikowski; Marco Metra; Dirk J van Veldhuisen; Adriaan A Voors Journal: Eur Heart J Date: 2020-05-14 Impact factor: 29.983
Authors: Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan Journal: Science Date: 2020-02-19 Impact factor: 47.728
Authors: Joan C Smith; Erin L Sausville; Vishruth Girish; Monet Lou Yuan; Anand Vasudevan; Kristen M John; Jason M Sheltzer Journal: Dev Cell Date: 2020-05-16 Impact factor: 12.270
Authors: Daniel W Lambert; Mike Yarski; Fiona J Warner; Paul Thornhill; Edward T Parkin; A Ian Smith; Nigel M Hooper; Anthony J Turner Journal: J Biol Chem Date: 2005-06-27 Impact factor: 5.157
Authors: Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell Journal: Front Physiol Date: 2014-06-24 Impact factor: 4.566